Last reviewed · How we verify
CD19-specific chimeric antigen receptor
At a glance
| Generic name | CD19-specific chimeric antigen receptor |
|---|---|
| Sponsor | Second Military Medical University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Lymphocyte count decreased
- Neutrophil count decreased
- White blood cell decreased
- Anemia
- Platelet count decreased
- Hypophosphatemia
- Hypotension
- Hyperglycemia
- Activated partial thromboplastin time prolonged
- Hypoxia
- Hyponatremia
- Fibrinogen decreased
Key clinical trials
- RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy (PHASE2, PHASE3)
- Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors (PHASE1)
- A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (PHASE1, PHASE2)
- Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma (PHASE1)
- A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases (PHASE1)
- A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE (PHASE1, PHASE2)
- A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma (PHASE2)
- Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: